Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Total 13F shares
-
54,613,642
-
Share change
-
+16,635,105
-
Total reported value
-
$422,156,729
-
Put/Call ratio
-
280%
-
Price per share
-
$7.73
-
Number of holders
-
123
-
Value change
-
+$130,257,296
-
Number of buys
-
72
-
Number of sells
-
53
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q1 2021
As of 31 Mar 2021,
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) was held by
123 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,613,642 shares.
The largest 10 holders included
Point72 Asset Management, L.P., BVF INC/IL, BlackRock Inc., VANGUARD GROUP INC, RA CAPITAL MANAGEMENT, L.P., STATE STREET CORP, VICTORY CAPITAL MANAGEMENT INC, PERCEPTIVE ADVISORS LLC, PRICE T ROWE ASSOCIATES INC /MD/, and RTW INVESTMENTS, LP.
This page lists
123
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.